Ameritas Investment Company LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Ameritas Investment Company LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, Holdings Channel.com reports. The fund purchased 3,399 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. BlackRock Inc. grew its position in Gilead Sciences by 12.2% during the 1st quarter. BlackRock Inc. now owns 124,723,133 shares of the biopharmaceutical company’s stock worth $8,060,854,000 after purchasing an additional 13,539,799 shares during the period. Norges Bank acquired a new stake in Gilead Sciences during the 4th quarter worth about $767,548,000. Nuveen Asset Management LLC grew its position in Gilead Sciences by 81.6% during the 1st quarter. Nuveen Asset Management LLC now owns 8,718,855 shares of the biopharmaceutical company’s stock worth $563,500,000 after purchasing an additional 3,918,666 shares during the period. Sarissa Capital Management LP acquired a new stake in shares of Gilead Sciences during the 1st quarter valued at about $174,332,000. Finally, Parnassus Investments CA grew its position in shares of Gilead Sciences by 56.8% during the 1st quarter. Parnassus Investments CA now owns 5,497,761 shares of the biopharmaceutical company’s stock valued at $355,320,000 after acquiring an additional 1,990,761 shares during the period. 76.78% of the stock is currently owned by institutional investors.

GILD has been the topic of a number of analyst reports. Oppenheimer initiated coverage on Gilead Sciences in a research report on Monday, June 28th. They set a “buy” rating and a $100.00 target price on the stock. Morgan Stanley raised their target price on Gilead Sciences from $81.00 to $83.00 and gave the company an “overweight” rating in a research report on Monday, May 3rd. Redburn Partners upgraded Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Tuesday, March 30th. SVB Leerink raised their target price on Gilead Sciences from $72.00 to $74.00 and gave the company an “outperform” rating in a research report on Friday, April 30th. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 30th. Ten equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $99.22.

GILD opened at $68.41 on Thursday. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.37 and a quick ratio of 1.18. The business has a 50 day simple moving average of $67.84. Gilead Sciences, Inc. has a 1-year low of $56.56 and a 1-year high of $77.25. The stock has a market cap of $85.80 billion, a price-to-earnings ratio of 9.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.02. Gilead Sciences had a net margin of 1.18% and a return on equity of 51.91%. The business had revenue of $6.42 billion for the quarter, compared to analyst estimates of $6.78 billion. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.05 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 29th. Stockholders of record on Tuesday, June 15th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 4.15%. The ex-dividend date was Monday, June 14th. Gilead Sciences’s payout ratio is presently 40.06%.

In other news, Director Richard James Whitley sold 20,282 shares of Gilead Sciences stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the sale, the director now owns 51,404 shares of the company’s stock, valued at approximately $3,319,156.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.12% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Article: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.